Methoxy Polyethylene Glycol-Epoetin Beta (Mircera®) Injection

Mircera is covered for anemia of chronic kidney disease in adults (on dialysis or non‑dialysis) and in pediatric patients 5–17 years only when converting from another ESA while on hemodialysis (pediatric use limited to conversion and given IV). Coverage requires documentation of CKD‑related anemia, dialysis status and age, adequate iron stores or active iron therapy, hemoglobin <10.0 g/dL for initial authorization (or <11.5 g/dL for those already on an ESA), prior ESA dosing and patient weight to calculate Mircera dosing, with approvals up to 12 months and specified dosing/frequency limits.

"Patient weight (for adult initial dosing calculated as 0."

Sign up to see full coverage criteria, indications, and limitations.